{"disease":{"id":"epstein-barr-virus-related-carcinoma","name":"epstein barr virus related carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05581550","title":"Somatostatin Receptor Imaging in NPC, EBV Related Cancers","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT04925544","title":"Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}